The ELGX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ELGX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ELGX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ELGX Detailed Price Forecast - CNN Money||View ELGX Detailed Summary - Google Finance|
|View ELGX Detailed Summary - Yahoo! Finance||View ELGX Stock Research & Analysis - Zacks.com|
|View ELGX Trends & Analysis - Trade-Ideas||View ELGX Major Holders - Barrons|
|View ELGX Call Transcripts - NASDAQ||View ELGX Breaking News & Analysis - Seeking Alpha|
|View ELGX Annual Report - CompanySpotlight.com||View ELGX OTC Short Report - OTCShortReport.com|
|View ELGX Fundamentals - TradeKing||View ELGX SEC Filings - Bar Chart|
|View Historical Prices for ELGX - The WSJ||View Performance/Total Return for ELGX - Morningstar|
|View the Analyst Estimates for ELGX - MarketWatch||View the Earnings History for ELGX - CNBC|
|View the ELGX Earnings - StockMarketWatch||View ELGX Buy or Sell Recommendations - MacroAxis|
|View the ELGX Bullish Patterns - American Bulls||View ELGX Short Pain Metrics - ShortPainBot.com|
|View ELGX Stock Mentions - StockTwits||View ELGX Stock Mentions - PennyStockTweets|
|View ELGX Stock Mentions - Twitter||View ELGX Investment Forum News - Investor Hub|
|View ELGX Stock Mentions - Yahoo! Message Board||View ELGX Stock Mentions - Seeking Alpha|
|View Insider Transactions for ELGX - SECform4.com||View Insider Transactions for ELGX - Insider Cow|
|View ELGX Major Holdings Summary - CNBC||View Insider Disclosure for ELGX - OTC Markets|
|View Insider Transactions for ELGX - Yahoo! Finance||View Institutional Holdings for ELGX - NASDAQ|
|View ELGX Stock Insight & Charts - FinViz.com||View ELGX Investment Charts - StockCharts.com|
|View ELGX Stock Overview & Charts - BarChart||View ELGX User Generated Charts - Trading View|
Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Posted on Friday January 11, 2019
Endologix, Inc. (ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to a newly hired executive (the “Awardee”). The awards were approved by the Company’s Compensation Committee, which is comprised of independent Directors, on December 10, 2018, as an inducement material to the Awardee’s entry into employment with the Company, as permitted under NASDAQ Listing Rule 5635(c)(4). The inducement grants to the Awardee consisted of (i) options (the “Options”) to purchase up to an aggregate of 250,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at an exercise price of $0.64 per share, and (ii) 150,000 restricted stock units (the “RSUs”).
Endologix Appoints John D. Zehren as Chief Commercial Officer
Posted on Thursday January 10, 2019
Endologix, Inc. (ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed John D. Zehren as the Company’s Chief Commercial Officer, effective as of January 7, 2019 (the “Effective Date”). Mr. Zehren brings to Endologix more than twenty years of commercial, sales and marketing, and business development experience in the medical device industry. Earlier in his distinguished career, Mr. Zehren spent over a decade at Edwards Lifesciences, the last four years of which were in the role of Vice President of Sales and Marketing.
Endologix Announces Fourth Quarter and Full-Year 2018 Preliminary Financial Results and Provides 2019 Financial Guidance
Posted on Monday January 07, 2019
Endologix, Inc. (the “Company”) (ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the fourth quarter ended December 31, 2018 is expected to be approximately $34 million. The Company reaffirms its previously issued annual guidance and continues to expect 2019 revenue of at least $140 million. The Company anticipates revenue for the first quarter ending March 31, 2019 of approximately $35 million.
Endologix Takes Decisive Action to Optimize Patient Outcomes by Ensuring Nellix System Used Only within Current Indications
Posted on Friday January 04, 2019
Endologix® Inc. (ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today that in order to ensure optimal outcomes for patients, unrestricted sales and use of the Nellix System will cease immediately, and the product will only be available for use under clinical protocol with pre-screened patients that adhere to the current indications. “We monitor the performance of the Nellix System through clinical trials, our complaint monitoring system, physician interaction and available publications,” said Dr. Matt Thompson, Chief Medical Officer of Endologix.